Drugs / Autologous alpha-DC1/TBVA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05127824 | Jul 2023 → Dec 2027 expected | clear cell renal carcinoma | Jodi Maranchie | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous alpha-DC1/TBVA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05127824 ↗ |
| Modality | Vaccine | “Autologous Tumor Blood Vessel Antigen (TBVA)-Dendritic Cell Vaccine” NCT05127824 ↗ |
| Route | Other | “receive neoadjuvant autologous Tumor Blood Vessel Antigen (TBVA)-Dendritic Cell Vaccine intradermally” NCT05127824 ↗ |